Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895112 | 1.00 | MAPT (0.42) | MAPTKITMAPK13MAPK12MAPK11 | |
| SCHEMBL2899849 | 0.79 | KDM4E (0.50) | MAPTPRKCQPRKCDGRM5 | |
| SCHEMBL2897776 | 0.79 | KDM4E (0.50) | MAPTPRKCQPRKCDGRM5 | |
| SCHEMBL3329389 | 0.79 | KDM4E (0.50) | MAPTPRKCQPRKCDGRM5 | |
| SCHEMBL3453428 | 0.78 | MAPT (0.48) | MAPT | |
| SCHEMBL3882295 | 0.77 | MAPK13 (0.46) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3882291 | 0.77 | MAPK13 (0.46) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3884627 | 0.77 | MAPK13 (0.46) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5477185 | 0.77 | GRM5 (0.41) | MAPTGRM5GSK3B | |
| SCHEMBL2214963 | 0.75 | HRH4 (0.34) | KITMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | MAPT 1115/4885KIT 2333/4885MAPK13 2894/4885 |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | MAPT 1549/4885KIT 2227/4885MAPK13 3597/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | MAPT 1070/4885KIT 2502/4885MAPK13 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.